Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mesalazine - Dr Falk Pharma

Drug Profile

Mesalazine - Dr Falk Pharma

Alternative Names: AJG501; Apriso; Mesalamine 0.375g extended-release capsules (Apriso) - Salix Pharmaceuticals; Mesalamine granules - Salix Pharmaceuticals; Salofalk; Salofalk Granu-Stix

Latest Information Update: 06 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dr Falk Pharma
  • Developer Ajinomoto; Dr Falk Pharma; Salix Pharmaceuticals
  • Class Aminosalicylic acids; Anti-inflammatories; Irritable bowel syndrome therapies; Small molecules
  • Mechanism of Action Lipoxygenase-cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Ulcerative colitis
  • Phase III Microscopic colitis
  • Phase II Colorectal cancer; Ulcerative proctitis
  • Discontinued Diverticulitis

Most Recent Events

  • 18 Aug 2017 Valeant Pharmaceuticals International completes a phase I trial for Ulcerative Colitis (In volunteers) in USA (NCT03327558)
  • 15 May 2017 Valeant Pharmaceuticals International initiates a phase I trial for Ulcerative Colitis (In volunteers) in USA (NCT03327558)
  • 16 Jan 2017 Dr Falk Pharma completes a phase III trial in Microscopic colitis in Netherlands, Spain, Lithuania, Czech Republic, Denmark, Belgium, Sweden, Hungary, Germany (EudraCT2008-005994-36)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top